Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sonnet Biotherapeutics Holdings Inc
(NQ:
SONN
)
0.7600
UNCHANGED
Streaming Delayed Price
Updated: 3:58 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Sonnet Biotherapeutics Holdings Inc
< Previous
1
2
3
Next >
Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering
August 19, 2021
PRINCETON, NJ / ACCESSWIRE / August 19, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update
August 16, 2021
Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update - Expanded F H AB Intellectual Property Portfolio - Completed $15.9 million At-The-Market Financing -...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Sonnet BioTherapeutics Announces Change in Date of Annual Meeting
June 14, 2021
- Annual Meeting to be Held Thursday July 15, 2021. PRINCETON, NJ / ACCESSWIRE / June 14, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a biopharmaceutical company developing innovative...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology
June 08, 2021
U.S. Patent and Trademark Office issued US Patent No. 11,028,166 for the Company's Fully Human Albumin Binding Domain Fusion Proteins PRINCETON, NJ / ACCESSWIRE / June 8, 2021 / Sonnet BioTherapeutics...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update
May 17, 2021
- SON-1010, fully-human IL-12 configured using FHAB platform, advancing towards IND submission - At-The-Market offering program resulted in net proceeds of $10.2 million PRINCETON, NJ / ACCESSWIRE /...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP)
May 10, 2021
- The No Observed Adverse Event Level (NOAEL) following repeated administration was more than 50 times the anticipated equivalent human clinical dose in NHP with no evidence of cytokine release...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Exposures
Product Safety
Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics
May 03, 2021
- New Life Therapeutics (NLT) to develop low-dose Interleukin 6 for Diabetic Peripheral Neuropathy in ASEAN territories - Upfront and potential milestone payments totaling up to $21 Million with up to...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.